This symposium issue consists of papers presented at the 22nd Annual Thomas A. Pitts Memorial Lectureship, April 7-8, 2016, in Charleston, South Carolina. The endowed lectureship, held annually since 1993, is funded by the Medical University of South Carolina Foundation through a bequest from Dr. Thomas A. Pitts, who served on MUSC's Board of Trustees for 36 years, including 25 years as its chair. The conference was presented by the Medical University of South Carolina, the Institute of Human Values in Health Care, the South Carolina Clinical and Translational Research Institute, and the Office of Continuing Medical Education of the MUSC College of Medicine.
Get full access to this article
View all access options for this article.
References
1.
D. J. R.Grey, “‘To Bring This Useful Invention into Fashion in England’: Mary Wortley Montagu as Medical Expert,” in T.Barnard, ed., British Women in the Intellectual World in the Long 18th Century (New York: Routledge. 2016): at 15-32.
2.
D. R.Hopkins, The Greatest Killer: Smallpox in History (Chicago: University of Chicago Press. 2002): at 80.
3.
R.Schwartz, “Drawing the Line at Age 14: Why Adolescents Should Be Able to Consent to Participation in Research,”Journal of Law, Medicine & Ethics45, no. 3 (2017): 295–306
4.
M. J.Cherry, “Adolescents Lack Sufficient Maturity to Consent to Medical Research,”Journal of Law, Medicine & Ethics45, no. 3 (2017): 307-317.
5.
E.Shuster, “Fifty Years Later: The Significance of the Nuremberg Code,”New England Journal of Medicine337 (1997): 1436-1440.
6.
R.Rhodes, “When Is Participation in Research a Moral Duty?”Journal of Law, Medicine & Ethics45, no. 3 (2017): 318-326.
7.
M.Yarborough, “Why There Is No Obligation to Participate in Clinical Research,”Journal of Law, Medicine & Ethics45, no. 3 (2017): 327-332.
8.
S. M.Wolf, “The Continuing Evolution of Ethical Standards for Genomic Sequencing in Clinical Care: Restoring Patient Choice,”Journal of Law, Medicine & Ethics45, no. 3 (2017): 333-340.
9.
L. E.Schnipper, “Central IRB Review Is an Essential Requirement for Cancer Clinical Trials,”Journal of Law, Medicine & Ethics45, no. 3 (2017): 341-347.
10.
M. R.Moon, “Can Central IRBs Replace Local Review?”Journal of Law, Medicine & Ethics45, no. 3 (2017): 348-351.
11.
L.Shepherd, “Informed Consent for Comparative Effectiveness Research Should Include Risks of Standard Care,”Journal of Law, Medicine & Ethics45, no. 3 (2017): 351-364.
12.
J. D.Lantos, “Informed Consent for Comparative Effectiveness Research Should Not Consider the Risks of the Standard Therapies That Are Being Studied as Risks of the Research,”Journal of Law, Medicine & Ethics45, no. 3 (2017): 365-374.
13.
S. S.Ellenberg and S.Joffe, “Studying Effects of Medical Treatments: Randomized Clinical Trials and the Alternatives,”Journal of Law, Medicine & Ethics45, no. 3 (2017): 375-381.
14.
U.Schüklenk and R.Smalling, “The Moral Case for Granting Catastrophically Ill Patients the Right to Access Unregistered Medical Interventions,”Journal of Law, Medicine & Ethics45, no. 3 (2017): 382-391.
